| Completed | Pharmacokinetic Study on G1090N (Nitazoxanide) Capsules in Healthy Volunteers Acute-on-Chronic Liver Failure | Phase 1 | 2025-08-26 |
| Terminated | A Study to See if an Investigational Medicine Called VS-01 Can Help and How Safe it is in the Treatment of Pat Hepatic Encephalopathy, Acute on Chronic Liver Failure (ACLF), Decompensated Cirrhosis | Phase 2 | 2025-08-25 |
| Recruiting | Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma Cholangiocarcinoma | Phase 1 / Phase 2 | 2023-08-21 |
| Terminated | Efficacy, Safety and Tolerability of VS-01 in Adult Patients With Acute-on-Chronic Liver Failure and Ascites ( Acute-On-Chronic Liver Failure, Ascites | Phase 2 | 2023-07-02 |
| Completed | Nitazoxanide Pharmacokinetic Parameters in Renal Impaired Subjects Renal Impairment, Renal Disease, Kidney Disease | Phase 1 | 2022-04-25 |
| Completed | Nitazoxanide Pharmacokinetic Parameters in Hepatic Impaired Patients Moderate Hepatic Impairment, Severe Hepatic Impairment, Liver Diseases | Phase 1 | 2021-11-05 |
| Completed | Elafibranor Pharmacokinetic Parameters in Elderly Healthy Volunteers Geriatrics, Healthy | Phase 1 | 2019-11-22 |
| Completed | Study to Investigate the Potential Drug-Drug Interaction Between Elafibranor and Indomethacin Drug-drug Interaction | Phase 1 | 2019-09-23 |
| Terminated | Study to Evaluate the Effect of Elafibranor on Hepatic Lipid Composition in Subjects With Nonalcoholic Fatty L Non-Alcoholic Fatty Liver | Phase 2 | 2019-08-16 |
| Terminated | Elafibranor, PK and Safety in Children and Adolescents 8 to 17 Years of Age With Non Alcoholic Steatohepatitis Non Alcoholic Steatohepatitis | Phase 2 | 2019-06-25 |
| Completed | Elafibranor Pharmacokinetic Parameters in Renal Impaired Patients Renal Impairment, Renal Insufficiency, Kidney Diseases | Phase 1 | 2019-02-28 |
| Completed | Elafibranor Pharmacokinetic Parameters in Hepatic Impaired Patients Hepatic Impairment, Liver Disease, Pharmacokinetics | Phase 1 | 2018-12-12 |
| Completed | Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) an Primary Biliary Cholangitis (PBC) | Phase 2 | 2017-04-05 |
| Terminated | Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Nonalcoholic Steatohepatitis (NASH) With Fibrosis | Phase 3 | 2016-03-01 |
| Completed | Mass Balance Study of 14C-labelled GFT505 in Healthy Volunteers Healthy | Phase 1 | 2014-04-01 |
| Completed | Phase I Study to Evaluate the Effect of GFT505 on QT/QTc Interval in Healthy Volunteers Healthy Volunteers | Phase 1 | 2014-02-01 |
| Completed | Phase IIb Study to Evaluate the Efficacy and Safety of GFT505 Versus Placebo in Patients With Non-Alcoholic St Non-Alcoholic Steatohepatitis (NASH) | Phase 2 | 2012-09-01 |
| Completed | Comparative Bioavailability - Gender Effect - Single and Multiple Ascending Dose Safety and Pharmacokinetic St Type 2 Diabetes, Diabetes Mellitus, Type 2, Metabolic Diseases | Phase 1 | 2011-11-01 |
| Completed | Pilot Study With GFT505 (80mg) in Patients With Insulin Resistance and Abdominal Obesity Insulin Resistance, Abdominal Obesity | Phase 2 | 2011-01-01 |
| Completed | Study With GFT505 (80mg) Versus Placebo in Patients With Type 2 Diabetes Mellitus Type II Diabetes Mellitus | Phase 2 | 2010-12-01 |
| Completed | Pilot Study With GFT505 (80mg) in Patients Presenting With Impaired Glucose Tolerance and Abdominal Obesity. Impaired Glucose Tolerance, Abdominal Obesity | Phase 2 | 2009-06-01 |
| Completed | Pilot Study With GFT505 (80mg) in Atherogenic Dyslipidaemic Patients With Abdominal Obesity Atherogenic Dyslipidaemia, Abdominal Obesity | Phase 2 | 2009-01-01 |